Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
6848 | 1360 | 27.4 | 79% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
1649 | 6378 | CONTRAST INDUCED NEPHROPATHY//NEPHROGENIC SYSTEMIC FIBROSIS//CONTRAST MEDIA |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | NEPHROGENIC SYSTEMIC FIBROSIS | Author keyword | 331 | 80% | 15% | 205 |
2 | NEPHROGENIC FIBROSING DERMOPATHY | Author keyword | 131 | 90% | 4% | 56 |
3 | GADOLINIUM | Author keyword | 47 | 12% | 26% | 350 |
4 | GADODIAMIDE | Author keyword | 45 | 64% | 3% | 44 |
5 | GADOLINIUM BASED CONTRAST AGENTS | Author keyword | 34 | 70% | 2% | 28 |
6 | NEPHROGENIC SYSTEMIC FIBROSIS NSF | Author keyword | 23 | 79% | 1% | 15 |
7 | GADOVERSETAMIDE | Author keyword | 23 | 100% | 1% | 10 |
8 | GADOTERIDOL | Author keyword | 22 | 66% | 2% | 21 |
9 | GADOBUTROL | Author keyword | 15 | 40% | 2% | 30 |
10 | GADOLINIUM CHELATES | Author keyword | 13 | 46% | 2% | 22 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | NEPHROGENIC SYSTEMIC FIBROSIS | 331 | 80% | 15% | 205 | Search NEPHROGENIC+SYSTEMIC+FIBROSIS | Search NEPHROGENIC+SYSTEMIC+FIBROSIS |
2 | NEPHROGENIC FIBROSING DERMOPATHY | 131 | 90% | 4% | 56 | Search NEPHROGENIC+FIBROSING+DERMOPATHY | Search NEPHROGENIC+FIBROSING+DERMOPATHY |
3 | GADOLINIUM | 47 | 12% | 26% | 350 | Search GADOLINIUM | Search GADOLINIUM |
4 | GADODIAMIDE | 45 | 64% | 3% | 44 | Search GADODIAMIDE | Search GADODIAMIDE |
5 | GADOLINIUM BASED CONTRAST AGENTS | 34 | 70% | 2% | 28 | Search GADOLINIUM+BASED+CONTRAST+AGENTS | Search GADOLINIUM+BASED+CONTRAST+AGENTS |
6 | NEPHROGENIC SYSTEMIC FIBROSIS NSF | 23 | 79% | 1% | 15 | Search NEPHROGENIC+SYSTEMIC+FIBROSIS+NSF | Search NEPHROGENIC+SYSTEMIC+FIBROSIS+NSF |
7 | GADOVERSETAMIDE | 23 | 100% | 1% | 10 | Search GADOVERSETAMIDE | Search GADOVERSETAMIDE |
8 | GADOTERIDOL | 22 | 66% | 2% | 21 | Search GADOTERIDOL | Search GADOTERIDOL |
9 | GADOBUTROL | 15 | 40% | 2% | 30 | Search GADOBUTROL | Search GADOBUTROL |
10 | GADOLINIUM CHELATES | 13 | 46% | 2% | 22 | Search GADOLINIUM+CHELATES | Search GADOLINIUM+CHELATES |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | DERMOPATHY | 342 | 72% | 20% | 270 |
2 | GADODIAMIDE | 150 | 68% | 10% | 130 |
3 | GADODIAMIDE INJECTION | 141 | 75% | 8% | 102 |
4 | GADOPENTETATE DIMEGLUMINE | 101 | 34% | 18% | 244 |
5 | GADOLINIUM EXPOSURE | 73 | 88% | 3% | 35 |
6 | GADOTERIDOL | 56 | 68% | 4% | 50 |
7 | ALTERNATIVE CONTRAST AGENT | 49 | 94% | 1% | 17 |
8 | NEPHROGENIC SYSTEMIC FIBROSIS | 34 | 19% | 12% | 164 |
9 | RENAL DIALYSIS PATIENTS | 24 | 63% | 2% | 24 |
10 | IODINATED CONTRAST | 23 | 45% | 3% | 38 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
---|---|---|---|---|
Current status of nephrogenic systemic fibrosis | 2014 | 11 | 64 | 98% |
Nephrogenic Systemic Fibrosis | 2012 | 30 | 42 | 100% |
Current Status of Gadolinium Toxicity in Patients with Kidney Disease | 2009 | 70 | 33 | 97% |
Application of Extracellular Gadolinium-based MRI Contrast Agents and the Risk of Nephrogenic Systemic Fibrosis | 2014 | 10 | 36 | 78% |
Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis | 2009 | 58 | 26 | 88% |
Minimizing Risk of Nephrogenic systemic fibrosis in Cardiovascular Magnetic Resonance | 2012 | 23 | 80 | 75% |
Nephrogenic fibrosing dermopathy: the first 6 years | 2003 | 165 | 11 | 82% |
MRI Safety Update 2008: Part I, MRI Contrast Agents and Nephrogenic Systemic Fibrosis | 2008 | 86 | 79 | 77% |
Risk Factors for NSF: A Literature Review | 2009 | 45 | 93 | 85% |
MRI contrast agents: Basic chemistry and safety | 2012 | 25 | 57 | 61% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | GLOBAL MED REGULATORY AFFAIRS | 12 | 86% | 0.4% | 6 |
2 | GLOBAL CLIN DEV DIAGNOST IMAGING | 4 | 75% | 0.2% | 3 |
3 | SCOTT WHITE CLIN HOSP | 4 | 32% | 0.7% | 10 |
4 | TRG DIAGNOST IMAGING | 2 | 36% | 0.4% | 5 |
5 | MED NEPHROL 3 | 2 | 67% | 0.1% | 2 |
6 | DIAGNOST RADIOL 54E2 | 2 | 23% | 0.5% | 7 |
7 | IMAGING SOLUT | 1 | 50% | 0.1% | 2 |
8 | RONTGEN STRAHLENKLIN | 1 | 50% | 0.1% | 2 |
9 | UO RISONANZA MAGNET | 1 | 50% | 0.1% | 2 |
10 | ZENT BILDGEBENDE DIAGNOST | 1 | 29% | 0.3% | 4 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000213055 | CO2 ANGIOGRAPHY//CARBON DIOXIDE ANGIOGRAPHY//CARBON DIOXIDE INJECTOR |
2 | 0.0000137376 | MR ANGIOGRAPHY//MAGNETIC RESONANCE MR VASCULAR STUDIES//MAGNETIC RESONANCE ANGIOGRAPHY |
3 | 0.0000101941 | RELAXIVITY//MRI CONTRAST AGENTS//GADOLINIUM COMPLEXES |
4 | 0.0000096954 | FLAIR//FLAIR SEQUENCE//CSF SUPPRESSION |
5 | 0.0000076974 | GD EOB DTPA//GADOXETIC ACID//GADOXETATE DISODIUM |
6 | 0.0000076204 | CONTRAST INDUCED NEPHROPATHY//CONTRAST INDUCED ACUTE KIDNEY INJURY//CONTRAST MEDIA |
7 | 0.0000073612 | ISOLATED MYELOPATHY//ENTANGLED HISTORIES//HLTH SCI MED RADIOL SCI |
8 | 0.0000069059 | MR RENOGRAPHY//FUNCTIONAL RENAL IMAGING//CORTICOMEDULLARY DIFFERENTIATION |
9 | 0.0000067031 | MOL MED MED BIOL ENGN//WATER PROTON RELAXIVITY//MOL SUR E PHYS NANOSCI |
10 | 0.0000059442 | RADIOGRAPHIC CONTRAST MEDIA//IOXAGLATE//CONTRAST MEDIA |